Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by stock analysts at Piper Jaffray Cos. in a research note issued to investors on Tuesday. They currently have a $447.00 price objective on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target points to a potential upside of 10.96% from the company’s previous close.

REGN has been the subject of several other reports. Canaccord Genuity reiterated a “hold” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, June 17th. Vetr upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $473.05 target price for the company in a research report on Monday, August 8th. Citigroup Inc. reiterated a “buy” rating and set a $470.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research report on Wednesday, June 29th. They set an “outperform” rating and a $400.00 target price for the company. Finally, Chardan Capital downgraded Regeneron Pharmaceuticals to a “sell” rating and set a $325.00 target price for the company. in a research report on Wednesday, June 8th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average price target of $470.91.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.85% during mid-day trading on Tuesday, reaching $406.24. 624,782 shares of the company traded hands. The firm has a 50 day moving average of $409.49 and a 200-day moving average of $389.48. The stock has a market capitalization of $42.51 billion, a PE ratio of 63.38 and a beta of 1.24. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-piper-jaffray-cos-2.html

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the company earned $2.89 earnings per share. The business’s revenue for the quarter was up 21.4% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals will post $10.93 EPS for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares in the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.